2023 ARCHIVES

Thank You for Your Support! Join Us Again Next Year on 19 - 21 March 2024

Missed Bioprocessing Summit Europe This Year?

Europe’s Premier Conference to Optimize Your Bioprocesses

14 - 15 March 2023

CELL CULTURE AND BIOPRODUCTION

ADVANCES IN RECOVERY AND PURIFICATION

GENE THERAPY CMC AND ANALYTICS

CELL THERAPY MANUFACTURING

ANALYTICS AND CHARACTERISATION

15 - 16 March 2023

CELL LINE DEVELOPMENT

INTENSIFIED AND CONTINUOUS PROCESSING

GENE THERAPY MANUFACTURING

CELL THERAPY CMC AND ANALYTICS

FORMULATION AND STABILITY

About the Bioprocessing Summit Europe

The Bioprocessing Summit Europe brings together 500+ bioproduction, analytical and formulation professionals to advance the manufacture, quality and control of biological and genetic therapies. This 3-day, 10 track meeting has quickly become a premier meeting in the European bioprocessing calendar and is regarded by many as “the fastest growing bioprocessing meeting in Europe” following record growth in 2022 – 350 to 500+ attendees - and a sold out Exhibit Hall.

We look forward to seeing you in Barcelona, or online, 14-16 March 2023, with expanded content on cell and gene therapy CMC and manufacturing, educational training seminars and a vastly bigger Exhibit Hall.

PLENARY KEYNOTES

EMERGING MODALITIES, PLATFORMS, AND TECHNOLOGIES – FROM mRNA TO PROTEINS

KEYNOTE PRESENTATION:
Overcoming CMC and Supply Chain Challenges for mRNA Technologies

Gregory Troiano
Chief Manufacturing Officer, mRNA Center of Excellence, Sanofi

KEYNOTE PRESENTATION:
Affinity Proteins for Biotechnological and Medical Purposes

Sophia Hober, PhD
Professor, School of Biotechnology, KTH Royal Institute of Technology

TRACK KEYNOTE SPEAKERS

Gyun Min Lee, PhD
Professor, Cell and Developmental Biology, KAIST, Korea

Arun Alphonse Ignatius, PhD
Director, Drug Product Sciences, Macrogenics, Inc., USA

Richard D. Braatz, PhD
Edwin R. Gilliland Professor, Chemical Engineering, Massachusetts Institute of Technology

Yves Durocher, PhD
Research Officer & Head, Mammalian Cell Expression, National Research Council Canada

Vered Caplan
CEO, Orgenesis, Inc.

James Reilly
Associate Director, Regeneron Pharmaceuticals Inc.

Ayda S. Mayer, PhD
Executive Director, Vector Core, REGENXBIO, Inc

Florence Salmon, PhD
Vice President, Regulatory Affairs and Preclinical Development, Ridgeline Discovery

Dan Bach Kristensen, PhD
Principal Scientist, Symphogen, Denmark

James Warren, PhD
Vice President, Pharmaceutical Development, Ultragenyx Pharmaceutical